Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA In Tug-Of-War Over Generic Cozaar/Hyzaar: Apotex And Roxane Sue Agency To Block Teva's Marketing Exclusivity

Executive Summary

FDA is engaged in a heated legal battle with Apotex and Roxane over its decision to grant Teva 180-day marketing exclusivity for generic versions of Merck's hypertension drugs Cozaar (losartan) and Hyzaar (losartan/hydrochlorothiazide)

You may also be interested in...

FDA Reluctantly Grants Teva Exclusivity For Cozaar And Hyzaar Generics

The agency says it has no choice but to award Teva exclusivity given an appeals court decision limiting forfeiture; Apotex has not decided whether it will challenge the court's ruling.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts